What is Minerva Neurosciences's market cap?

Minerva Neurosciences (NERV) has a market capitalization of $195.9M and trades on NASDAQ.

Who are Minerva Neurosciences's competitors?

Minerva Neurosciences's key competitors include Acadia Pharmaceuticals, Bristol-Myers Squibb, Cyclerion Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Minerva Neurosciences partner with?

Minerva Neurosciences's notable partners include Tanabe Pharma Corporation, Janssen Pharmaceutica NV, Royalty Pharma plc, and others.

What subsidiaries does Minerva Neurosciences have?

Minerva Neurosciences's subsidiaries include Mind-NRG Sarl.

Where is Minerva Neurosciences headquartered?

Minerva Neurosciences is headquartered in United States of America and employs approximately 9 people. It has been publicly traded since 2014.

Minerva Neurosciences

NERV

Minerva Neurosciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) diseases.

Market cap

$195.91M+1,367%

Table of contents

Earnings

Q1 2026 report

May 5, 2026

EPS-$0.17Miss by $0.04

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

EPS estimate-$0.19

Competitors

By market cap

Bristol-Myers Squibb$127.75B+32.1%

Praxis Precision Medicines, Inc.$8.8B+677%

Acadia Pharmaceuticals$4.3B+14.8%

LBR

LB Pharmaceuticals Inc Common Stock$997.4M—

Neumora Therapeutics, Inc.$307.6M-16.6%

Minerva Neurosciences$195.9M+1,234%

NRX Pharmaceuticals, Inc.$155.4M+172%

Cyclerion Therapeutics$15.2M+53.1%

By revenue growth

Acadia Pharmaceuticals+9.9%

Bristol-Myers Squibb+1.8%

By net margin

Acadia Pharmaceuticals34.3%+11.3pp

Bristol-Myers Squibb15.01%+3.8pp

Praxis Precision Medicines, Inc.-3,658.53%—

Profile

Minerva Neurosciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) diseases. The company's primary focus is addressing significant unmet medical needs in patients with schizophrenia, particularly the debilitating negative symptoms for which there are currently no approved treatments in the United States.

Competitive position

A clinical-stage developer of a potential first-in-class monotherapy for the negative symptoms of schizophrenia, currently navigating the FDA confirmatory trial process.

GeographiesUnited States, European Union, Latin America

Customer segmentsHealthcare systems, Psychiatric patients

Business modelR&D-stage biopharmaceutical, Licensing and royalties

SuppliersContract manufacturing organizations, Clinical research organizations, Raw material suppliers, Academic research institutions

CustomersSpecialized sales forces, Pharmaceutical distributors, Hospitals and psychiatric clinics, Third-party payors

CountryUnited States of America

Listed2014

Employees9.0

CEORemy Luthringer

SectorHealthcare

IndustryBiotechnology

Websiteminervaneurosciences.com

FilingsSEC EDGAR

Questions, answered.

What is Minerva Neurosciences's market cap?: Minerva Neurosciences (NERV) has a market capitalization of $195.9M and trades on NASDAQ.
Who are Minerva Neurosciences's competitors?: Minerva Neurosciences's key competitors include Acadia Pharmaceuticals, Bristol-Myers Squibb, Cyclerion Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Minerva Neurosciences partner with?: Minerva Neurosciences's notable partners include Tanabe Pharma Corporation, Janssen Pharmaceutica NV, Royalty Pharma plc, and others.
What subsidiaries does Minerva Neurosciences have?: Minerva Neurosciences's subsidiaries include Mind-NRG Sarl.
Where is Minerva Neurosciences headquartered?: Minerva Neurosciences is headquartered in United States of America and employs approximately 9 people. It has been publicly traded since 2014.